Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
503
Total raised
£3.8B
disclosed amounts
This month
£36.9M
raised so far
AlbionVC led the Series B round to fund the digital health platform's expansion into the American market.
"We’re on a mission to become a household name across the world and our Series B funding is just the start. We already dominate Europe’s employer-funded gender-based healthcare market. With our growing team in the US and numerous big brands already choosing Peppy, we will soon be a leading player in America."
Octopus Ventures led the Series A round with participation from Hoxton Ventures and Route66 Ventures.
"Diagnosing and treating ADHD can be a long and costly process, and living with the symptoms can be extremely challenging. We want to help our members make significant improvements to their quality of life by giving them the tools to better understand themselves, and implement coping strategies that actually work."
The medtech firm has raised $36m in a round led by Oppenheimer Holdings to accelerate its product pipeline and scale American operations.
"We are excited to have Oppenheimer and British Patient Capital join our mission to create safer and more accurate imaging technologies that will help clinicians shorten patients' diagnostic and treatment journeys,"
The clinical stage pharmaceutical company raised the capital from Mankind Pharma to advance its lead cancer cachexia asset.
"We are thrilled to announce the successful closing of this financing round, which brings our total seed funding to £10 million, well ahead of our original target. The financing includes support from both longstanding and new investors, notably Mankind Pharma, demonstrating confidence in our strategic goal to develop innovative globally approved treatments for cancer cachexia and other muscle wasting conditions. We are particularly pleased by the support from Mankind and warmly welcome Atish Majumdar to our Board of Directors. With these funds, we will complete feasibility activities for the clinical development programme for S-pindolol benzoate, which has shown promising potential efficacy in this area of major unmet need."
IW Capital backs healthcare provider GPDQ with £2.6m to support ongoing expansion.
"IW Capital is proud to invest in GPDQ as the company continues to expand. GPDQ is a market disruptor in the healthcare space. Its phenomenal growth, proven track record, strong client base and plans to maximise growth in the post-Covid world has impressed the team at IW Capital. We are committed to providing GPDQ with the capital to enable them to expand at pace and support them, particularly as there is a growing demand for healthcare services and resources since the pandemic."
-1.png)
